Artificial Intelligence in Prostate Cancer VL

Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski

Details
Zach Klaassen speaks with Mark Markowski about the advancements in AI, particularly the ArteraAI Prostate Test, and its implications for prostate cancer treatment. Dr. Markowski explains how ArteraAI has evolved from predicting treatment responses in localized prostate cancer to potentially guiding treatment decisions in metastatic hormone-sensitive prostate cancer. The CHAARTED study, a pivotal t...

Optimizing Salvage Radiation Therapy in Prostate Cancer: New AUA/ASTRO/SUO Guideline - Todd Morgan

Details
Zach Klaassen speaks with Todd Morgan about innovative approaches in the management of prostate cancer post-prostatectomy. Dr. Morgan presents compelling new data on the prostate AI test, highlighting its use in identifying biochemical recurrence after prostatectomy. This AI model, validated with data from key trials, not only distinguishes patients based on the aggressiveness of their disease but...

Predicting Response to Hormone Therapy in Prostate Cancer With a Post-Prostatectomy MMAI Model - Todd Morgan

Details
Zach Klaassen discusses with Todd Morgan about innovative post-prostatectomy biomarkers. Dr. Morgan presents findings on a new AI model developed by ArteraAI for assessing biochemical recurrence in prostate cancer patients post-prostatectomy. This model, validated using clinical data and digital pathology from two significant trials, shows high predictive accuracy. It aims to distinguish patients...

NCCN 2024 Guidelines Endorse Novel Prostate Test for Precision Risk Stratification - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the emergence of the ArteraAI Prostate Test for risk stratification in prostate cancer management. This innovative test, now considered a predictive model, marks a significant advance, providing more accurate risk assessments for biochemical recurrence, distant metastasis, and prostate can...

Multimodal AI Informing Treatment Decisions in Advanced Prostate Cancer - Gerhardt Attard

Details
Alicia Morgans interviews Gerhardt Attard about groundbreaking research presented at ESMO 2023, utilizing the STAMPEDE data set. They discuss a new prognostic tool developed with Artera, the ArteraAI Prostate Score, which predicts prostate cancer-specific mortality using digitized images of H&E slides from over 3,300 patients. This tool has proven that primary tumor analysis can provide significan...

The Artera AI Model: Advancing Personalized Medicine in Prostate Cancer Treatment | Dan Spratt & Alicia Morgans Discuss NEJM Evidence Manuscript

Details
Dan Spratt joins Alicia Morgans in a conversation on the Artera AI multimodal artificial intelligence model manuscript published in the NEJM Evidence. The Artera predictive model for prostate cancer is a significant advancement in personalized medicine for patients with localized prostate cancer. Unlike prognostic biomarkers that help identify patients at lower or higher risk of developing recurre...

Personalizing Prostate Cancer Therapy Using AI-based Predictive Biomarkers - Paul Nguyen

Details
In a discussion with Alicia Morgans, Paul Nguyen highlights the advancing role of predictive biomarkers in prostate cancer treatment. He distinguishes between prognostic and predictive biomarkers, emphasizing the unique value of the latter in tailoring the right amount of treatment for individual patients. They focus on the development of a commercial test by Artera that predicts responses to shor...

Artera Multi-Modal AI Platform - Guiding Treatment Decisions in Men with Prostate Cancer - Andre Esteva & Felix Feng

Details
Andre Esteva and Felix Feng join Alicia Morgans to discuss the Artera MMAI platform in prostate cancer intended to identify patients who will benefit from therapy intensification and help guide treatment decisions for men with high-risk localized prostate cancer. Artera has developed a unique multi-modal artificial intelligence (MMAI) algorithm composed of two pieces. One piece learns from imagery...

Beyond the NCCN Localized Prostate Cancer Risk Category: The MMAI Prognostic Risk Stratification Model - Jonathan Tward

Details
Jonathan Tward joins Alicia Morgans to discuss advancing prognostic capabilities in prostate cancer risk stratification using multimodal deep learning with digital histopathology within the context of a series of NRG Oncology phase III trials. The Artera AI prognostic biomarker model is based on five prospectively randomized trials of over 5,500 patients with low-risk prostate cancer on radiation...

Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer - Daniel Spratt

Details
Alicia Morgans and Daniel Spratt discuss an AI-derived multi-modal digital pathology-based biomarker test designed towards improving risk stratification in high risk prostate cancer and then supporting personalized treatment decisions in these men. Biographies: Daniel Spratt, MD, Chair, Department of Radiation Oncology, UH Cleveland Medical Center Professor, CWRU School of Medicine, Cleveland, OH...